HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

The estrogen clearance cascade has three enzymatic layers. Phase 1 hydroxylation via CYP1A1 and CYP1B1. Phase 2 inactivation via methylation (COMT) and sulfation (SULT1A1). And a third layer that most hormone conversations never reach — glutathione conjugation, the backstop that catches what the first two layers miss. The enzymes that execute this backstop are encoded by GSTM1 and GSTT1, two members of the glutathione S-transferase family. What makes them unlike every other gene in the Women's Hormone panel is the nature of their key variant: not a single nucleotide substitution but a complete deletion — a structural absence of the gene itself. Women with null GSTM1 or null GSTT1 don't have a slower version of these enzymes. They have no enzyme at all. The PlexusDx Precision Peptide Genetic Test analyzes GSTM1 and GSTT1 deletion status as part of 14 pathways, 49 peptides, and 150+ genetic insights — mapping the glutathione layer of estrogen detoxification within the full Reproductive Health pathway.

Glutathione S-Transferases: What They Are and What They Do

Glutathione S-transferases (GSTs) are a superfamily of cytosolic detoxification enzymes that catalyze the conjugation of reduced glutathione (GSH) to electrophilic substrates — converting reactive compounds into water-soluble, excretable glutathione conjugates. GSH conjugation is one of the body's primary defenses against reactive oxygen species, environmental toxins, carcinogens, and chemically reactive endogenous metabolites.

In estrogen biology, GSTM1 and GSTT1 serve a specific and critical function: they conjugate the reactive quinone metabolites produced when catechol estrogens — particularly 4-OHE2 (4-hydroxyestradiol) — are not rapidly methylated by COMT or sulfated by SULT1A1 and instead undergo further oxidation:

The oxidation cascade: CYP1B1 converts estradiol to 4-OHE2 → if COMT and SULT1A1 cannot clear 4-OHE2 quickly, one-electron oxidation produces 4-OHE2 semiquinone → two-electron oxidation produces 4-OHE2 quinone (4-OHE2-Q). 4-OHE2 quinones are highly reactive electrophiles that form depurinating DNA adducts — covalently bonding to adenine and guanine bases in DNA and triggering their removal from the DNA backbone. These abasic sites are mutagenic if not repaired. Glutathione conjugation by GSTM1 and GSTT1 intercepts 4-OHE2 quinones before they reach DNA, converting them to stable glutathione conjugates that are safely excreted.

GSTM1 and GSTT1 are therefore the final enzymatic line of defense in the 4-OHE2 detoxification pathway — the layer that becomes most consequential exactly when upstream clearance by COMT and SULT1A1 is most impaired.

The Null Deletion: A Different Kind of Genetic Variant

Most genetic variants are single nucleotide polymorphisms — point changes in a gene's sequence that alter protein structure or expression. GSTM1 and GSTT1 null alleles are structurally different. They are copy number deletions: entire chromosomal segments carrying the GSTM1 or GSTT1 gene are absent from the genome. A woman with homozygous null genotype carries zero functional copies of the deleted gene — producing no enzyme whatsoever.

This binary architecture is critical to understanding the genetic risk profile. Unlike COMT Val158Met — where Met/Met homozygotes have reduced but not absent enzyme activity — GSTM1 null and GSTT1 null represent complete enzymatic absence rather than reduced function. There is no intermediate null. You either have GSTM1 or you don't.

GSTM1 deletion prevalence: Approximately 40–50% of individuals of European ancestry carry the GSTM1 null genotype, making it one of the most common functional gene deletions in the human genome. Prevalence varies substantially by ancestry — null frequencies reach 50–60% in some East Asian populations and are approximately 20–30% in African-ancestry populations in most published frequency estimates. Roughly half of all women have zero GSTM1 enzyme activity, with no clinical signs and no routine testing unless specifically genotyped.

GSTT1 deletion prevalence: Approximately 10–20% of European-ancestry individuals carry the GSTT1 null genotype. GSTT1 null is substantially more common in East Asian populations — 40–60% null in several large studies — and less common in African-ancestry populations at approximately 20–25%. Like GSTM1, GSTT1 null produces complete enzymatic absence.

Double null (GSTM1 null + GSTT1 null): Because both deletions are common and independent, double null is a meaningful genotype category. In European-ancestry populations, the expected double null frequency under independence is approximately 5–10%. Double null women have no GSTM1 and no GSTT1 — the glutathione conjugation layer of estrogen quinone detoxification is entirely absent. When combined with slow COMT and low SULT1A1, this leaves only non-enzymatic antioxidant defenses against reactive 4-OHE2 quinones.

GSTM1 vs GSTT1: Different Enzymes, Overlapping Roles

GSTM1 and GSTT1 are structurally related but belong to different GST subfamilies — mu (GSTM) and theta (GSTT) — with overlapping but not identical substrate profiles in estrogen metabolism:

GSTM1 (Glutathione S-Transferase Mu 1) is highly expressed in liver, lung, and other metabolically active tissues. Within the estrogen detoxification cascade, GSTM1 has been the more extensively studied of the two for catechol estrogen quinone conjugation. Its activity directly processes 4-OHE2-derived quinones before they reach DNA. GSTM1 is also the primary enzyme handling oxidative stress byproducts from CYP1A1/CYP1B1-mediated estrogen metabolism — including reactive oxygen species generated during the hydroxylation reactions themselves. Women who are GSTM1 null face both reduced quinone clearance and increased oxidative burden from Phase 1 reactions.

GSTT1 (Glutathione S-Transferase Theta 1) is expressed in erythrocytes, liver, and peripheral tissues. Its substrate profile overlaps with GSTM1 for some reactive estrogen metabolites, but GSTT1 is particularly active against smaller electrophilic compounds — including certain quinone epoxides and halogenated substrates. In the estrogen clearance context, GSTT1 provides complementary protection alongside GSTM1 rather than a fully redundant one: loss of both genes removes protection at multiple overlapping but distinct substrate points in the quinone detoxification pathway.

The combined GSTM1/GSTT1 system operates as a two-enzyme glutathione conjugation layer. When one is absent, the other provides partial coverage of the reactive estrogen quinone substrate pool. When both are absent, coverage is nil.

Why Null Status Compounds Other Clearance Deficits

GSTM1 and GSTT1 null status matters most in the context of the other Women's Hormone panel genetics — specifically when upstream clearance enzymes are also impaired. The escalating combinations:

High CYP1B1 activity + null GSTM1/GSTT1: CYP1B1 Leu432Val high-activity variants increase 4-OHE2 production from estradiol — providing more reactive substrate for quinone formation. Women who simultaneously produce more 4-OHE2 and lack GSTM1/GSTT1 glutathione conjugation face a compounded burden: more reactive substrate generated, less enzymatic capacity to neutralize it. The context covered in CYP1A1 and CYP1B1: Estrogen Metabolism Pathways explains what drives 4-OHE2 production at Phase 1.

Slow COMT + null GSTM1/GSTT1: COMT Met/Met reduces the primary methylation clearance of 4-OHE2. When COMT is slow, more 4-OHE2 remains available for oxidation to reactive quinones — increasing demand on GSTM1/GSTT1 glutathione conjugation at exactly the point where their absence is most consequential. A woman with Met/Met COMT and double null GSTM1/GSTT1 has both primary methylation clearance and glutathione backup absent. The COMT dimension is covered in COMT Val158Met and Estrogen Clearance.

His/His SULT1A1 + null GSTM1/GSTT1: Low SULT1A1 sulfation reduces the parallel catechol estrogen inactivation route — increasing the proportion of catechol estrogens that remain available for quinone-forming oxidation. Combined with absent GSTM1/GSTT1, neither the sulfation backup nor the glutathione backup is available. The SULT1A1 context is covered in SULT1A1 Sulfation: Estrogen Detox Genetics.

Slow COMT + low SULT1A1 + null GSTM1/GSTT1: The most genetically challenged clearance architecture in the panel. MTHFR-impaired SAMe limits COMT below its Val158Met genotypic capacity. His/His SULT1A1 provides near-absent sulfation backup. Null GSTM1/GSTT1 eliminates glutathione conjugation entirely. In the context of any estrogen-pathway support that elevates estradiol — providing more Phase 1 substrate for CYP1B1 to convert to 4-OHE2 — all three Phase 2 pathways are simultaneously at their minimum capacity. This is the risk profile that the full 6-insight Reproductive Health panel is uniquely positioned to surface.

Glutathione as a Substrate: Why GSH Supply Matters Too

GSTM1 and GSTT1 enzyme activity depends on two things: the presence of the enzymes themselves (determined by deletion status) and an adequate supply of reduced glutathione (GSH) as the conjugation substrate. Even in women with functional GSTM1 and GSTT1 genotypes, depleted GSH levels reduce conjugation capacity.

GSH is a tripeptide (glycine-cysteine-glutamate) synthesized intracellularly. Its availability depends on adequate dietary cysteine and glycine, sufficient glutathione reductase activity to regenerate oxidized glutathione (GSSG) back to GSH, and the overall oxidative burden the cell is managing. Women under high oxidative stress — from chronic inflammation, environmental toxin exposure, high CYP1B1-driven reactive metabolism, or nutritional deficiency — face lower GSH availability precisely when glutathione conjugation demand is highest.

Supporting GSH levels through nutritional strategies — N-acetylcysteine (NAC) as a cysteine precursor, glycine-rich foods, liposomal glutathione — is a practical clinical consideration for women who are GSTM1 or GSTT1 null and facing high reactive estrogen metabolite burden. These are not protocol prescriptions; they are the nutritional context a provider weighs when a woman's full panel shows null deletion status alongside impaired upstream clearance genetics.

Xenobiotic and Oxidative Stress Protection Beyond Estrogen

GSTM1 and GSTT1 are not estrogen-specific enzymes — they are broad-spectrum detoxification proteins that process a wide range of electrophilic and oxidative substrates. Their null status has documented associations in the research literature with differential response to environmental exposures, medication metabolism, and oxidative stress burden across multiple biological systems.

This broader detoxification role is relevant in the hormonal health context because estrogen metabolism is not the only source of reactive compounds that the glutathione system must manage. CYP1A1 and CYP1B1 metabolize environmental polycyclic aromatic hydrocarbons (PAHs) and other xenobiotics alongside estrogens, generating reactive metabolites that GSTM1 and GSTT1 must also process. A woman who is GSTM1 null faces depleted glutathione conjugation capacity for both estrogen quinones and environmentally-derived reactive metabolites simultaneously — a compounded oxidative burden that blood panels cannot quantify but genetics surfaces as a baseline predisposition.

GSTM1 and GSTT1 in the Full Women's Hormone Genetic Panel

GSTM1 and GSTT1 are one of 6 Reproductive Health insights the Precision Peptide Genetic Test analyzes as a connected system — the glutathione layer within the full estrogen detoxification architecture covered in the Complete Guide to Genetic Women's Hormone Testing. Their specific connections in the panel:

CYP1B1 — the primary producer of GSTM1/GSTT1's quinone substrates. CYP1B1 hydroxylates estradiol to 4-OHE2; when 4-OHE2 is not cleared by COMT or SULT1A1, it oxidizes to quinones that GSTM1/GSTT1 must conjugate. High-activity CYP1B1 variants and null GSTM1/GSTT1 are the Phase 1/Phase 2 mismatch that matters most for reactive estrogen metabolite accumulation. CYP1A1 and CYP1B1: Estrogen Metabolism Pathways covers Phase 1 in full.

COMT — primary Phase 2 methylation upstream of GSTM1/GSTT1 protection. COMT Met/Met reduces methylation-dependent 4-OHE2 clearance, routing more substrate toward quinone formation and therefore toward GSTM1/GSTT1-dependent detoxification. COMT and GSTM1/GSTT1 are functionally complementary — both protect against 4-OHE2 quinone accumulation through different enzymatic mechanisms. COMT Val158Met and Estrogen Clearance covers methylation in full.

MTHFR — upstream SAMe supply constraining COMT. MTHFR-impaired SAMe limits COMT activity — increasing catechol estrogen dwell time and quinone formation risk, raising the demand on GSTM1/GSTT1 as the backup. MTHFR and Methylation: The Women's Hormone Connection covers the methylation cycle.

SULT1A1 — parallel Phase 2 sulfation upstream of GSTM1/GSTT1 protection. His/His SULT1A1 eliminates the sulfation backup for catechol estrogens, increasing quinone formation risk in parallel with slow COMT. GSTM1/GSTT1 backstop both simultaneously when each is impaired — and the absence of all three defines the most compromised Phase 2 architecture in the panel. SULT1A1 Sulfation: Estrogen Detox Genetics covers sulfation in full.

ESR1 / ESR2 — receptor sensitivity to estrogens that less-cleared reactive metabolites extend at tissue level. 4-OHE2 itself is an estrogen receptor ligand — slower glutathione clearance of 4-OHE2-derived reactive species extends both their genotoxic and their receptor-activating potential at target tissues. Combined with high ESR1 sensitivity, null GSTM1/GSTT1 amplifies the net estrogenic signal from the reactive metabolite burden. Estrogen Receptor Genetics: ESR1 and ESR2 Variants covers receptor genetics in full.

What Your GSTM1 and GSTT1 Results Can and Cannot Tell You

GSTM1 and GSTT1 deletion status reveals whether you carry functional copies of these genes — whether the glutathione conjugation layer of estrogen quinone detoxification is present or absent at the enzymatic level. Results do not measure your current glutathione level, DNA adduct burden, or overall oxidative stress status; those require specialized laboratory testing. They do not diagnose any clinical condition. And they do not predict your response to any specific estrogen-pathway compound or hormone protocol.

What they deliver is the tertiary clearance picture: whether your glutathione backstop is available when COMT and SULT1A1 face their highest demand, and — most importantly — whether the compounding combination of impaired COMT, absent SULT1A1, and null GSTM1/GSTT1 applies to your individual genetics. That combination, invisible in bloodwork, is precisely what the full 6-insight Reproductive Health panel is designed to surface. Genetics as a guide, not a guarantee — and as one of 6 Reproductive Health insights within 14 total pathways and 150+ genetic insights, GSTM1 and GSTT1 complete the Phase 2 clearance picture that no individual enzyme test can capture alone.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to understand your GSTM1 and GSTT1 deletion status and how glutathione detox fits your complete hormone clearance profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions About GSTM1, GSTT1, and Hormone Detox

What do GSTM1 and GSTT1 null deletions mean in the Precision Peptide Genetic Test?

GSTM1 and GSTT1 null deletions mean those genes are completely absent — producing zero enzyme activity rather than reduced activity. Approximately 40–50% of women are GSTM1 null; 10–20% are GSTT1 null. Both null together eliminates the glutathione conjugation backstop against reactive estrogen quinones. Part of 6 Reproductive Health insights within 14 pathways, 150+ genetic insights.

How does GSTM1 null status affect estrogen clearance?

GSTM1 conjugates 4-OHE2-derived quinones — the reactive estrogen metabolites produced when COMT and SULT1A1 cannot clear 4-OHE2 quickly. GSTM1 null eliminates this glutathione backstop entirely. Combined with slow COMT or His/His SULT1A1, all three Phase 2 clearance routes are impaired — a combination the Precision Peptide Genetic Test surfaces across 6 Reproductive Health insights.

Can glutathione levels be supported if I am GSTM1 or GSTT1 null?

GSTM1 and GSTT1 null status cannot be changed — the genes are absent. However, supporting glutathione substrate availability through NAC, glycine, and dietary antioxidants maintains GSH supply for residual conjugation capacity. Providers weigh this nutritional context alongside full panel results, within 14 pathways and 150+ genetic insights from the Precision Peptide Genetic Test.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.